UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

APRIL 20, 2007 (APRIL 17, 2007)
Date of Report (Date of earliest event reported)

DELCATH SYSTEMS, INC.

(Exact name of registrant as specified in its charter)

DELAWARE 001-16133
(State or other jurisdiction (Commission File No.)
of incorporation)

06-1245881 (IRS Employer Identification No.)

1100 SUMMER STREET STAMFORD, CT 06905

(Address of principal executive offices, including zip code)

Registrant's telephone number, including area code: (203) 323-8668

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligations of the registrant under any of the following provisions (see General Instruction A.2. below):

Written communications pursuant to Rule 425 under the Securities Act (17

	CFR 230.425)						`
I_I	Soliciting material pursuant to R 240.14a-12)	ule 14a-12	under	the	Exchange	Act (17	CFR
1_1	Pre-commencement communications Exchange Act (17 CFR 240.14d-2(b))	•	to R	ule	14d-2(b)	under	the
1_1	Pre-commencement communications	pursuant	to R	ule	13e-4(c)	under	the

ITEM 5.02. DEPARTURE OF DIRECTORS OR CERTAIN OFFICERS; ELECTION OF DIRECTORS; APPOINTMENT OF CERTAIN OFFICERS; COMPENSATORY ARRANGEMENTS OF CERTAIN OFFICERS.

On April 17, 2007, Delcath Systems, Inc. (the "Company") announced the resignations on that date of two members of its Board of Directors, Mark A. Corigliano and Daniel L. Isdaner, effective immediately. The resignation letters submitted by Messrs. Corigliano and Isdaner did not reference any disagreement with the Company on any matter relating to the Company's operations, policies and practices.

A copy of the press release announcing the resignations is attached as Exhibit 99.1.

ITEM 9.01 FINANCIAL STATEMENTS AND EXHIBITS.

Exchange Act (17 CFR 240.13e-4(c))

- (d) Exhibits
- 99.1 Press Release entitled "Delcath Systems Announces Board Resignations," dated April 17, 2007.

SIGNATURES

Pursuant to the requirements of amended, the registrant has duly caus signed on its behalf by the undersigned	sed th	·
Dated: April 20, 2007		DELCATH SYSTEMS, INC.
	By:	/s/ Richard L. Taney Name: Richard L. Taney Title: Chief Executive Officer

EXHIBIT INDEX

EXHIBIT NUMBER	DESCRIPTION
99.1	Press Release entitled "Delcath Systems Announces Board Resignations," dated April 17, 2007.

[DELCATH LOGO]

DELCATH SYSTEMS ANNOUNCES BOARD RESIGNATIONS

STAMFORD, CONN.--APRIL 17, 2007--Delcath Systems, Inc. (Nasdaq: DCTH) announced the resignations of two members of its Board of Directors: Mr. Mark A. Corigliano and Mr. Daniel L. Isdaner, effectively immediately.

Mr. Richard L. Taney, Chief Executive Officer of Delcath, commented: "We thank Mark and Dan for their service on our Board and are particularly grateful for their efforts and assistance during our recent management transition. We wish them continued success in their endeavors."

Mr. Taney added, "We are actively seeking replacements for these open board positions and look forward to filling them with professionals from within the medical community or by individuals with public company experience."

ABOUT DELCATH SYSTEMS, INC.

Delcath Systems is a developer of percutaneous perfusion technology for organ or region-specific delivery of therapeutic and chemotherapeutic agents. The Company's intellectual property portfolio currently consists of 12 patents on a worldwide basis, including the United States, Europe, Asia and Canada. For more information, please visit the Company's website, www.delcath.com.

THIS RELEASE CONTAINS FORWARD-LOOKING STATEMENTS, WHICH ARE SUBJECT TO CERTAIN RISKS AND UNCERTAINTIES THAT CAN CAUSE ACTUAL RESULTS TO DIFFER MATERIALLY FROM THOSE DESCRIBED. FACTORS THAT MAY CAUSE SUCH DIFFERENCES INCLUDE, BUT ARE NOT LIMITED TO, UNCERTAINTIES RELATING TO OUR ABILITY TO SUCCESSFULLY COMPLETE PHASE III CLINICAL TRIALS AND SECURE REGULATORY APPROVAL OF OUR CURRENT OR FUTURE DRUG-DELIVERY SYSTEM AND UNCERTAINTIES REGARDING OUR ABILITY TO OBTAIN FINANCIAL AND OTHER RESOURCES FOR ANY RESEARCH, DEVELOPMENT AND COMMERCIALIZATION ACTIVITIES. THESE FACTORS, AND OTHERS, ARE DISCUSSED FROM TIME TO TIME IN OUR FILINGS WITH THE SECURITIES AND EXCHANGE COMMISSION. YOU SHOULD NOT PLACE UNDUE RELIANCE ON THESE FORWARD-LOOKING STATEMENTS, WHICH SPEAK ONLY AS OF THE DATE THEY ARE MADE. WE UNDERTAKE NO OBLIGATION TO PUBLICLY UPDATE OR REVISE THESE FORWARD-LOOKING STATEMENTS TO REFLECT EVENTS OR CIRCUMSTANCES AFTER THE DATE THEY ARE MADE.